Article
Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease.
Scientific reports - 25 Feb 2021
Lidberg Kevin A, Annalora Andrew J, Jozic Marija, Elson Daniel J, Wang Lu, Bammler Theo K, Ramm Susanne, Monteiro Maria Beatriz, Himmelfarb Jonathan, Marcus Craig B, Iversen Patrick L, Kelly Edward J
Abstract excerpt
CYP3A5 is the primary CYP3A subfamily enzyme expressed in the human kidney and its aberrant expression may contribute to a broad spectrum of renal disorders. Pharmacogenetic studies have reported inconsistent linkages between CYP3A5 expression and hypertension, however, most investigators have considered CYP3A5*1 as active and CYP3A5*3 as an inactive allele. Observations of gender specific differences in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.